Key Takeaways

• Lycia remains the clearest active offering: 14.7 million shares at a proposed $16–$18, with Friday October 23 a tentative trading date.
• At the $17 midpoint, the base offering would raise $249.9 million gross. That finances development; it does not establish clinical success.
• Bitari and Starton still have conflicting calendars. Web3Labs is postponed according to IPOScoop; a displayed date is not confirmation of trading.
• A single calendar also lists Davion for October 22. Its timetable and terms remain unconfirmed; no final pricing or completed debut was verified.

IPO Week Preview

October 22, 2026 | Week October 19–23, 2026

With staff and AI research assistance By Frank Whitaker and Stan Rosenberg

Research cutoff: 2026-10-22T02:29:25-06:00

Frank: the company behind the ticker

What caught my attention at Lycia is the ambition to remove disease-related proteins. The company is developing treatments for allergic and autoimmune conditions. Its official overview describes technology that carries unwanted proteins into cells for disposal. [4] Its pipeline includes food allergy and Graves’ disease. These are possible future patients and markets, rather than established medicine sales. [3][6]

Stan: what investors would pay

At $17, Lycia’s 14.7 million new shares imply $249.9 million gross and estimated $227.8 million net proceeds. Its 52,094,559 post-offering shares imply $885.6 million basic equity value, excluding additional potential shares. [3]

June 30 cash and marketable securities totaled $148.1 million. Management projects funding into the second half of 2029, supporting allergy and Graves’ programs and other operations. Costs or trial outcomes could shorten that estimate. [3]

Trials, regulatory review and competition remain hurdles. More funding cannot establish clinical success. [3]

Frank on the unsettled calendar

Bitari’s SEC amendment proposes 4,285,715 shares at $7. Yet IPOScoop places it in the week of October 19 while Webull shows November 5. The Texas company describes digital infrastructure on its website; the filing is the place to examine the hosting business and offering terms. Neither calendar proves that shares have begun trading. [1][8][10][13]

Starton develops continuous delivery technology for cancer medicines. IPOScoop lists 6.7 million shares at $5–$7 with a date to be announced; Webull shows October 23 at $6. Those entries do not establish final terms. Web3Labs, which serves blockchain businesses in Hong Kong, remains marked postponed by IPOScoop despite Webull’s October 22 entry. [5][12][13]

Davion Healthcare appears for October 22 on The Right Trader, but not on the principal weekly calendars checked. It belongs on the watchlist with its uncertainty intact, not among confirmed debuts. [14]

Dates worth checking next

Thursday October 22 is Webull’s offering-end date for Lycia, not a verified pricing announcement. Friday October 23 remains the tentative first-trade date in IPOScoop. No trading time was verified. The next decisive evidence would be final terms or an official listing announcement. [1][13]

At the research cutoff, Lycia’s news and pipeline pages and Bitari’s website yielded no additional specifically dated future investor meeting, earnings call or presentation. Nasdaq’s public IPO page provided no usable dated confirmation in the retrieved view. [15] This is a finding about the pages checked, not a claim that either company has no news. [6][7][10]

Sources

[1] IPOScoop calendar: tentative dates and status. https://www.iposcoop.com/ipo-calendar/ [2] Renaissance calendar: independent weekly cross-check. https://www.renaissancecapital.com/IPO-Center/Calendar [3] Lycia SEC amendment October 20: terms, finances and funding. https://www.sec.gov/Archives/edgar/data/1806540/000162828026066381/lyciatherapeutics-sx1a.htm [4] Lycia overview: leadership and scientific approach. https://lyciatx.com/about/overview/ [5] IPOScoop Web3Labs: business, former terms and postponement. https://www.iposcoop.com/ipo/web3labs-global-of-hong-kong/ [6] Lycia pipeline: clinical stages and development plans. https://lyciatx.com/pipeline/programs/ [7] Lycia news: announcements and future-event check. https://lyciatx.com/news/ [8] Bitari SEC amendment October 14: terms, management and control. https://www.sec.gov/Archives/edgar/data/2091680/000118518526004746/bitaris1a3101326.htm [10] Bitari official site: business and future-event check. https://bitari.ai/ [12] IPOScoop Starton: conflicting terms and TBA date. https://www.iposcoop.com/ipo/starton-holdings/ [13] Webull calendar: conflicting Bitari and Web3Labs dates. https://www.webullapp.com/quote/us/ipo?hl=en [15] Nasdaq IPO page: official listing check; no usable dated confirmation retrieved. https://www.nasdaq.com/market-activity/ipos [14] The Right Trader calendar: unconfirmed Davion watchlist lead. https://therighttrader.com/ipo-calendar